The data showed that 68% of the 34 patients evaluated for tumor response had clinical benefit. Ten patients had partial responses (eight confirmed, two not yet confirmed), and 13 patients had stable disease as their best response. All seven patients with activating EGFR mutations experienced tumor shrinkage (six PRs and one SD), and three patients with wild type EGFR achieved partial responses.
XL647 was generally well-tolerated and showed pharmacodynamic target modulation in an ongoing Phase I study evaluating daily dosing in patients with advanced solid tumors.
George Scangos, president and CEO of Exelixis, said: “The Phase II data continue to show encouraging anti-tumor activity for XL647 given on an intermittent schedule in previously untreated clinically selected non-small cell lung cancer patients (NSCLC) patients. We are pleased to continue to see evidence of good tolerability and no grade 3 rash with XL647, and believe that a daily dosing strategy may have the potential to further enhance the anti-tumor activity in NSCLC.”